Logo

IP Update: Recent Patents Awarded to Loma Linda, Quark Pharmaceuticals, and More

Jan 30, 2014
Premium

Title: Apoptotic Cell-mediated Transfection of Mammalian Cells with Interfering RNA

Patent Number: 8,637,476

Filed: Oct. 4, 2010

Lead Inventor: Fengchun Li, Loma Linda University

Title: Antigenic Compositions and Use of Same in the Targeted Delivery of Nucleic Acids

Patent Number: 8,637,477

Filed: Aug. 29, 2008

Lead Inventor: Rajan George, Akshaya Bio

Title: Methods for Treating Chronic Kidney Disease

Patent Number: 8,637,482

Filed: June 7, 2010

Lead Inventor: Elena Feinstein, Quark Pharmaceuticals

Filed under

Gene Editing, Gene Silencing, & CRISPR
Business News
RNAi
intellectual property
USPTO
Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.